Loading
XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.
XNW5004 is a small-molecule drug developed by Evopoint Biosciences. Its target is EZH2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in follicular lymphoma and prostate cancer. The largest, NCT06702995, plans to enrol 307 participants with primary completion was scheduled for 2026-05-13 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at EZH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to EZH2.
1.XNW5004 slips into a pocket on EZH2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"XNW5004" OR ABSTRACT:"XNW5004" OR TITLE:"EZH2i" OR ABSTRACT:"EZH2i") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about XNW5004, not a curated reading list.
Shares Evopoint Biosciences and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.